Document is current
Any future updates will be listed below
-
Authors
Braanaas, Karoline S.
Dammen, Toril
Fagerland, Morten W.
Husebye, Einar
Leinaas, Amund
Schirmer, Henrik
Sverre, Elise
Aune, Erlend
Myhre, Peder L.
Munkhaugen, John
-
Funding
Funding for this research was provided by:
Vestre Viken Hospital Trust
- License Information
-
More Information
Article History
Received: 19 January 2026
Revised: 8 April 2026
Accepted: 13 April 2026
First Online: 22 April 2026
Declarations
:
: PLM: No conflicts related to the present manuscript. Has served on advisory boards and/or received speaker fees from Amarin, AmGen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Gentian, Novartis, Novo Nordisk, Pharmacosmos, Roche, Sanofi, US2.ai and Vifor, and is a member of the Editorial Board of Heart Failure Reviews. HS: Has received lecture fees from Amgen, Astra Zeneca, Biogen, Boehringer Ingelheim Novartis, Novo-Nordisk and Pharmacosmos.
